XML 39 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Geographic Information and Concentrations
 12 Months Ended
Dec. 31, 2023
Risks and Uncertainties [Abstract]  
Geographic Information and Concentrations GEOGRAPHIC INFORMATION AND CONCENTRATIONS
Revenues are attributed to geographical areas based on the location at which we earned revenue for product sales of IBSRELA and XPHOZAH or the domicile of our collaboration partners. A summary of our revenue by geographic areas for the years ended December 31, 2023, 2022 and 2021, is as follows (in thousands):
Year Ended December 31,
202320222021
United States (1)$83,276 $15,600 $— 
International:
Asia Pacific (2)41,121 36,527 10,084 
North America (3)59 31 13 
Total revenue$124,456 $52,158 $10,097 
(1)Revenues from the United States are primarily comprised of amounts earned from sales of IBSRELA and XPHOZAH, as well as the upfront license fee from the METiS Agreement.
(2)Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 Kyowa Kirin Agreement, the 2019 Kyowa Kirin Agreement and the Fosun Agreement.
(3)Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.
Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December 31, 2023, 2022 and 2021 were as follows:
Year Ended December 31,
202320222021
Kyowa Kirin29.0 %70.0 %100.0 %
Bioridge Phama24.0 %3.2 %— %
Cardinal19.8 %9.6 %— %
AmerisourceBergen Drug Corporation19.1 %11.1 %— %
McKesson15.7 %8.9 %— %